Advertisement

Topics

Mylan preps for rejection of Advair copy

06:32 EDT 14 Jun 2018 | BioPharmaDive

The generic drugmaker faces another regulatory setback for its copycat version of the blockbuster GSK lung drug.

Original Article: Mylan preps for rejection of Advair copy

NEXT ARTICLE

More From BioPortfolio on "Mylan preps for rejection of Advair copy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...